Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide consolidation after tandem autologous/allogeneic transplant for high-risk multiple myeloma
ACTRN12616000777493Phase 2Completed
- Sponsor
- Alfred Health
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in multiple myeloma (MM), sponsored by Alfred Health. Primary endpoint: Safety and tolerability of lenalidomide post-allogeneic stem cell transplant. Started Mar 2015; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12616000777493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000777493.